<DOC>
	<DOCNO>NCT00053924</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness perifosine treat patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Perifosine Treating Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy perifosine , term 6-month survival , patient advance adenocarcinoma pancreas . - Determine safety tolerability drug patient . - Determine median survival time 1-year survival rate patient treat drug . - Determine objective response rate ( partial complete ) , response duration , time progression patient treat drug . - Determine toxicity drug patient . OUTLINE : Patients receive oral perifosine daily 3 week . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 17-37 patient accrue study within 15 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas amenable curative local therapy Metastatic OR locally advance No know brain metastases No ascites require therapeutic paracentesis least 2 occasion within past 6 week PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN ( 5 time ULN liver metastasis ) Renal Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Gastrointestinal No gastrointestinal ( GI ) tract disease result inability take oral medication requirement IV alimentation No uncontrolled inflammatory bowel disease No active peptic ulcer disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction attribute compound similar chemical biological composition perifosine No active malignant disease could interfere interpretation study result No ongoing active infection No uncontrolled concurrent illness No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No 1 prior chemotherapy regimen metastatic locally advanced disease Prior chemotherapy , give radiosensitizer , allow addition singleline therapy At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy Not specify Radiotherapy At least 3 week since prior radiotherapy likely myelotoxic effect ( 3,000 cGy field include substantial marrow ) recover Surgery No prior GI surgery affect absorption Other No concurrent antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>